These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 9184209

  • 1. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.
    Böttinger EP, Jakubczak JL, Roberts IS, Mumy M, Hemmati P, Bagnall K, Merlino G, Wakefield LM.
    EMBO J; 1997 May 15; 16(10):2621-33. PubMed ID: 9184209
    [Abstract] [Full Text] [Related]

  • 2. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM.
    Cancer Res; 1999 Oct 01; 59(19):4834-42. PubMed ID: 10519393
    [Abstract] [Full Text] [Related]

  • 3. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
    Gorska AE, Joseph H, Derynck R, Moses HL, Serra R.
    Cell Growth Differ; 1998 Mar 01; 9(3):229-38. PubMed ID: 9543389
    [Abstract] [Full Text] [Related]

  • 4. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
    Amendt C, Schirmacher P, Weber H, Blessing M.
    Oncogene; 1998 Jul 09; 17(1):25-34. PubMed ID: 9671311
    [Abstract] [Full Text] [Related]

  • 5. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H.
    Oncogene; 2007 Jul 19; 26(33):4850-62. PubMed ID: 17297450
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
    Crowley MR, Frost A, Chen DT, Baffi MO, Nicola T, Serra R.
    Differentiation; 2006 Feb 19; 74(1):40-52. PubMed ID: 16466399
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M.
    Clin Cancer Res; 2001 Sep 19; 7(9):2931-40. PubMed ID: 11555612
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
    Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM.
    Cancer Res; 1997 Dec 15; 57(24):5564-70. PubMed ID: 9407968
    [Abstract] [Full Text] [Related]

  • 14. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M.
    Cancer Res; 2004 Aug 01; 64(15):5200-11. PubMed ID: 15289325
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X, Bellis S, Yan Z, Friedman E.
    Cell Growth Differ; 1999 Jan 01; 10(1):11-8. PubMed ID: 9950213
    [Abstract] [Full Text] [Related]

  • 17. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y, Kyprianou N.
    Cancer Res; 1999 Mar 15; 59(6):1366-71. PubMed ID: 10096572
    [Abstract] [Full Text] [Related]

  • 18. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
    Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR, Salhab KF, McGrath P, Strodel W, Freeman JW.
    Anticancer Res; 2000 Mar 15; 20(1A):43-51. PubMed ID: 10769633
    [Abstract] [Full Text] [Related]

  • 19. Loss of TGF-beta signaling contributes to autoimmune pancreatitis.
    Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, Green JE, Kim SJ.
    J Clin Invest; 2000 Apr 15; 105(8):1057-65. PubMed ID: 10772650
    [Abstract] [Full Text] [Related]

  • 20. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Go C, Li P, Wang XJ.
    Cancer Res; 1999 Jun 15; 59(12):2861-8. PubMed ID: 10383147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.